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Sir,
We read with great interest the article recently published
in Brain by Anttonen et al. (2017) reporting a homozygous
p.Ser31Leu mutation in the ZNHIT3 gene causing PEHO
(progressive encephalopathy with peripheral oedema, hyp-
sarrhythmia, and optic atrophy) syndrome (MIM 260565)
in a series of affected children from Finland.
PEHO was ﬁrst described in the Finnish population (Salonen
et al., 1991) and the diagnostic criteria (Supplementary Table
1) were initially formulated by Somer in 1993 (Somer, 1993;
Somer et al., 1993). While the description of PEHO in siblings
born from healthy and sometimes consanguineous parents sup-
ports autosomal recessive inheritance (Riikonen, 2001), from a
genetic point of view PEHO syndrome has remained a poorly
understood condition until recently.
The affected Finnish children reported by Anttonen et al.
showed the classical clinical and radiological features of
PEHO syndrome and were all found to harbour a founder
p.Ser31Leu homozygous mutation in ZNHIT3, suggesting a
common ancestral origin of these families. Supporting this
Finnish founder effect, in the ExAC database containing
60706 individuals (last accessed April 2017) the p.Ser31Leu
variant represents the most frequent single nucleotide
polymorphism in ZNHIT3 (rs148890852), being carried by
30 (of a total of 39) subjects from a cohort of 3298 Finnish
individuals [minor allele frequency (MAF): 0.0045; carriers
frequency: 0.009]. Notably, in all remaining ethnic groups
the variant is present at a much lower frequency with only
ﬁve carriers from 31694 (non-Finnish) Europeans (MAF:
7.888  105; carrier frequency: 0.0001), and it is (almost)
absent in some other populations (e.g. Asian, Latino).
The ZNHIT3 gene is likely to be important in the PEHO
group of disorders from different populations, we therefore
analysed our whole-exome and whole-genome data from a
cohort of well-deﬁned PEHO syndrome (n = 9) and ‘PEHO-
like’ syndrome (n = 15) cases from variable (non-Finnish)
ancestries and failed to identify additional mutations in
ZNHIT3. Although a rare condition, based on the carrier
frequency data from publicly available databases and on
the screening analysis from our disease cohort, we suggest
that autosomal recessive PEHO syndrome due to ZNHIT3
mutations is likely to be exceptionally rare outside of
Finland (especially in association with the isolated founder
p.Ser31Leu mutation).
There are many examples of genetic isolated in families
from Finland (Sajantila et al. 1996; Pakkasja¨rvi et al.,
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2006). This is because the Finnish population have an iso-
lated ancestry in a small founder group, followed by several
historical bottle neck events that have led to genetic drift
and enrichment of certain rare and low frequency variants
that are almost absent in other ethnicities (Abecasis et al.,
2012; Lemmela¨ et al., 2016). Although PEHO could be
considered a very rare syndrome, it has been reported
worldwide, including from Australia (Field et al., 2003),
Turkey (Tekgu¨l and Tu¨tu¨ncu¨og˘lu, 2000), Japan (Fujimoto
et al., 1995), South America (Caraballo et al., 2011) and
different European countries (Nieto-Barrera et al., 2003;
Klein et al., 2004); overall, non-Finnish patients account
for approximately half of the cases published to date
(Langlois et al., 2016; Anttonen et al., 2017).
These data suggest genetic heterogeneity, a well-known
scenario in many neurodevelopmental and neurodegenera-
tive disorders caused by mutations in different genes impli-
cated in overlapping conditions characterized by severe
progressive encephalopathy and epilepsy (Noebels et al.,
2012). In addition, certain broad phenotypes associated
with the PEHO main features should be also considered
based on previous clinical reports of patients lacking any
of the mandatory diagnostic criteria that have been diag-
nosed with ‘PEHO-like’ disorders (Chitty et al., 1996; Field
et al., 2003; Pavlidou et al., 2016). In this regard, an auto-
somal dominant de novo mutation in CDKL5 has been
previously identiﬁed in a single proband with a PEHO-
like disorder (Gawlinski et al., 2016) and a recent report
described a young female with PEHO syndrome harbour-
ing a de novo missense mutations in KIF1A (Langlois et al.,
2016). Furthermore, a homozygous truncating mutation of
the CCDC88A gene was recently found as a cause of
PEHO-like syndrome in a consanguineous family and the
authors identiﬁed a similar neurological phenotype in the
Ccdc88a knock-out mouse presenting progressive micro-
cephaly and corpus callosum deﬁciency (Nahorski et al.,
2016).
Importantly, we recently characterized a new autosomal
recessive neurodevelopmental and degenerative disorder
caused by biallelic mutations in PRUNE1, with some of
the affected individuals showing PEHO or PEHO-like fea-
tures (Zollo et al., 2017). PRUNE1 is a member of the
DHH (Asp-His-His) phosphoesterase and exopolyphospha-
tase protein superfamily of molecules important for cell
motility, and implicated in cancer progression
(Tammenkoski et al., 2008). Of interest, we found that
pathogenic mutations cause enhancement of PRUNE1 en-
zymatic exopolyphosphatase (PPase/PPX) activity and
mutated PRUNE1 colocalizes with microtubules during mi-
tosis to form mitotic spindle via binding to /b-tubulin and
also demonstrated that PRUNE1 mutants cause a delay in
microtubule polymerization, particularly affecting the nu-
cleation-phase (Zollo et al., 2017; Ferrucci et al., unpub-
lished results).
In one of the reported families from our original study
(Family C), we identiﬁed a homozygous p.D106N mutation
involving an aspartic acid residue of the active and
conserved DHH motif (Fig. 1A–C). Interestingly, the pheno-
type of the affected siblings from this family fulﬁlled the
diagnostic criteria for PEHO syndrome, including severe
hypotonia with onset shortly after birth and profound
global developmental delay, early loss of visual ﬁxation
(Fig. 1D and E) and optic atrophy, normal head circumfer-
ence at birth evolving to progressive microcephaly (Fig. 1F
and G), infantile epileptic encephalopathy with hypsarrhyth-
mia, and progressive CNS atrophy mainly involving the
cerebellum and the brainstem (Fig. 1H and I). In addition,
probands from the family showed some of the typical
distinctive facial features (e.g. narrow forehead, short nose
and open mouth appearance; Fig. 1D–G), and variably
presented many of the additional supportive criteria for
the diagnosis of PEHO, including a progressive white
matter involvement on brain MRI (Fig. 1J and K), facial
and/or limb oedema, abnormal brainstem auditory evoked
potentials, brisk tendon reﬂexes in early childhood and slow-
ing of the peripheral nerve conduction velocity in late
infancy.
As the most important neuropathology features in PEHO
syndrome are classically observed at the cerebellar level due
to severe loss of granule cells and abnormal Purkinje cells,
we analysed the PRUNE1 protein expression in a develop-
ing mouse cerebellum in order to better understand the role
of PRUNE1 in the disease. In this regard, immunoﬂuores-
cence analyses show that murine PRUNE1 protein is
strongly expressed along the entire cerebellum collected at
postnatal Day P1 (Fig. 2A), either in the granular layers or
in the developing Purkinje cells, with particular enrichment
of the expression in Purkinje cells migrating to the cerebel-
lar surface (Fig. 2B). Taken together, present and previous
data suggest the importance of PRUNE1 during the prolif-
eration, migration and differentiation processes of granular
and Purkinje neuron precursor cells, possibly also through
an effect on microtubules dynamic during cell division
(Carotenuto et al., 2006; Zollo et al., 2017).
Interestingly, the CCDC88A gene recently associated to
PEHO-like syndrome with polymicrogyria (MIM 260565)
encodes girdin, a protein involved in postnatal neural devel-
opment and cancer progression that has also been suggested
to play an important role in cytoskeleton organization, via ei-
ther a possible direct association to microtubules (Simpson
et al., 2005) or a localization (and interaction) with a
number of cytoskeleton- and microtubule-binding proteins
(Ota et al., 2013). Furthermore, another PEHO-like pheno-
type variably characterized by hypotonia, severe psycho-
motor delay, infantile epileptic encephalopathy with optic
atrophy, abnormal visual and brainstem evoked potentials,
brisk tendon reﬂexes, microcephaly, CNS progressive atro-
phy (mainly affecting cerebellum and brainstem) with white
matter involvement (Fig. 1L–O), has been recently described
in a number of families in association with biallelic muta-
tions of TBCD, a gene encoding one of the ﬁve co-chaper-
ones required for assembly of the /b-tubulin heterodimer
that is crucial in cytoskeleton organization (Flex et al.,
2016; Miyake et al., 2016).
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Figure 1 Family tree, Sanger sequencing, multiple-sequence alignment of PRUNE p.D106N family, and clinico-radiological
natural history of PRUNE1- and TBCD- associated tubulinopathies with PEHO and PEHO-like features. (A) Pedigree from the
Family carrying the p.D106N change in PRUNE1 (corresponding to Family C from Zollo et al., 2017). (B) Electropherograms of carrier parent and
affected sibs from the family. (C) Multiple-sequence alignment showing complete conservation of DHH motif (in red) of PRUNE1 orthologues
across species. The aspartic acid residue replaced by the p.D106N mutation is indicated with an arrow; non-conserved residues are underlined in
yellow. (D) Patient II-2 at 4 months of age, note the early loss of visual fixation.(E) Patient II-3 at 2 months of age, note the early loss of visual
fixation. (F and G) Patient II-3 at the age of 16 months; note the hypotonia and distinctive facial features, including narrow forehead and open
mouth appearance. Brain MRIs showing sagittal views of Patient II-3 at 6 months (H) and 16 months of age (I) show progressive global brain
atrophy but more specifically there is evidence of cerebellar and brain stem atrophy. Axial views images in the same patient (II-3) at 6 months
(J) and 16 months of age (K) shows progressive diffuse white matter abnormalities along with progressive brain atrophy. Brain MRIs performed in
two affected siblings carrying the homozygous p.P1122L change in TBCD showing sagittal views from the first patient (Patient F118_347; from
Flex et al., 2016) at the age of 8 months (L) and his affected brother (Patient F118_347) at the age of 2 years (M). There is progression of CNS
atrophy from early mild cortical atrophy and thin corpus callosum to (L) to cortical and subcortical brain atrophy mainly involving cerebellum
(vermis and folia) and the brainstem (M). Axial views of the two siblings also show progression of white matter involvement (N and O).
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It is uncertain if mutations in the ZNHIT3 share the
disease mechanisms associated to tubule dysfunction;
using knockdown and genome editing experiments in zeb-
raﬁsh embryos and knockdown experiments in mouse cere-
bellar neurons, Anttonen et al. showed that ZNHIT3 is
essential in cerebellar granule neuron survival and migra-
tion. Of interest, results from a large interactome network
analysis recently identiﬁed a direct interaction between
ZNHIT3 and the cytoskeleton associated protein 5,
encoded by CKAP5 (Hein et al., 2015); however, further
studies will be needed to assess a possible role of ZNHIT3
in cytoskeleton assembly and organization.
In conclusion, the recent characterization of new autosomal
recessive disorders associated with defects in proteins that
regulate cytoskeleton microtubule dynamics and inﬂuence
neuronal migration imply heterogeneity in the PEHO spec-
trum of disorders and highlight a Finnish founder effect in
the ZNHIT3 gene. Thus, we suggest that in addition to
ZNHIT3 the screening of additional disease-causing genes
(including PRUNE1, TBCD and CCDC88A) should be con-
sidered in patients presenting with PEHO or PEHO-like
features.
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